Bayer Healthcare Company Profile
✉ Email this page to a colleague
What is the competitive landscape for BAYER HEALTHCARE, and what generic alternatives to BAYER HEALTHCARE drugs are available?
BAYER HEALTHCARE has twenty-nine approved drugs.
There are twenty-eight US patents protecting BAYER HEALTHCARE drugs. There is one tentative approval on BAYER HEALTHCARE drugs.
There are four hundred and twenty-four patent family members on BAYER HEALTHCARE drugs in fifty-nine countries and forty-nine supplementary protection certificates in seventeen countries.
Summary for Bayer Healthcare
International Patents: | 424 |
US Patents: | 28 |
Tradenames: | 24 |
Ingredients: | 14 |
NDAs: | 29 |
Patent Litigation for Bayer Healthcare: | See patent lawsuits for Bayer Healthcare |
Drugs and US Patents for Bayer Healthcare
Applicant | Tradename | Generic Name | Dosage | NDA | Approval Date | TE | Type | RLD | RS | Patent No. | Patent Expiration | Product | Substance | Delist Req. | Exclusivity Expiration |
---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
Bayer Healthcare Llc | CLARITIN REDITABS | loratadine | TABLET, ORALLY DISINTEGRATING;ORAL | 021993-001 | Dec 12, 2006 | OTC | Yes | Yes | ⤷ Try a Trial | ⤷ Try a Trial | |||||
Bayer Healthcare Llc | CLARITIN | loratadine | CAPSULE;ORAL | 021952-001 | Jun 16, 2008 | OTC | Yes | Yes | ⤷ Try a Trial | ⤷ Try a Trial | |||||
Bayer Healthcare | LAMPIT | nifurtimox | TABLET;ORAL | 213464-002 | Aug 6, 2020 | RX | Yes | Yes | ⤷ Try a Trial | ⤷ Try a Trial | |||||
Bayer Healthcare Llc | MYCELEX-7 | clotrimazole | CREAM;VAGINAL | 018230-002 | Dec 26, 1991 | DISCN | No | No | ⤷ Try a Trial | ⤷ Try a Trial | |||||
Bayer Healthcare | VITRAKVI | larotrectinib sulfate | SOLUTION;ORAL | 211710-001 | Nov 26, 2018 | RX | Yes | Yes | 9,782,414 | ⤷ Try a Trial | ⤷ Try a Trial | ||||
Bayer Healthcare | VITRAKVI | larotrectinib sulfate | SOLUTION;ORAL | 211710-001 | Nov 26, 2018 | RX | Yes | Yes | 10,045,991 | ⤷ Try a Trial | ⤷ Try a Trial | ||||
>Applicant | >Tradename | >Generic Name | >Dosage | >NDA | >Approval Date | >TE | >Type | >RLD | >RS | >Patent No. | >Patent Expiration | >Product | >Substance | >Delist Req. | >Exclusivity Expiration |
Expired US Patents for Bayer Healthcare
Applicant | Tradename | Generic Name | Dosage | NDA | Approval Date | Patent No. | Patent Expiration |
---|---|---|---|---|---|---|---|
Bayer Healthcare Llc | CLARITIN | loratadine | SYRUP;ORAL | 020641-002 | Nov 27, 2002 | 6,132,758 | ⤷ Try a Trial |
Bayer Healthcare Llc | MYCELEX | clotrimazole | CREAM;TOPICAL | 018183-001 | Approved Prior to Jan 1, 1982 | 3,660,577 | ⤷ Try a Trial |
Bayer Healthcare Llc | CLARITIN | loratadine | TABLET;ORAL | 019658-002 | Nov 27, 2002 | 4,659,716*PED | ⤷ Try a Trial |
Bayer Healthcare Llc | SHADE UVAGUARD | avobenzone; octinoxate; oxybenzone | LOTION;TOPICAL | 020045-001 | Dec 7, 1992 | 4,522,807 | ⤷ Try a Trial |
Bayer Healthcare Llc | CLARITIN | loratadine | TABLET;ORAL | 019658-002 | Nov 27, 2002 | 4,863,931*PED | ⤷ Try a Trial |
Bayer Healthcare Llc | CLARITIN REDITABS | loratadine | TABLET, ORALLY DISINTEGRATING;ORAL | 020704-002 | Nov 27, 2002 | 4,863,931*PED | ⤷ Try a Trial |
>Applicant | >Tradename | >Generic Name | >Dosage | >NDA | >Approval Date | >Patent No. | >Patent Expiration |
International Patents for Bayer Healthcare Drugs
Country | Patent Number | Estimated Expiration |
---|---|---|
European Patent Office | 3218380 | ⤷ Try a Trial |
European Patent Office | 2042504 | ⤷ Try a Trial |
Singapore | 11201703962X | ⤷ Try a Trial |
Japan | 2015214590 | ⤷ Try a Trial |
Portugal | 2493858 | ⤷ Try a Trial |
Portugal | 3699181 | ⤷ Try a Trial |
>Country | >Patent Number | >Estimated Expiration |
Supplementary Protection Certificates for Bayer Healthcare Drugs
Patent Number | Supplementary Protection Certificate | SPC Country | SPC Expiration | SPC Description |
---|---|---|---|---|
2493858 | C20200015 00323 | Estonia | ⤷ Try a Trial | PRODUCT NAME: DAROLUTAMIID;REG NO/DATE: EU/1/20/1432 30.03.2020 |
2493858 | 2090018-9 | Sweden | ⤷ Try a Trial | PRODUCT NAME: DAROLUTAMIDE OPTIONALLY IN THE FORM OF A PHARMACEUTICALLY ACCEPTABLE SALT OR ESTER THEREOF; REG. NO/DATE: EU/1/20/1432/001 20200330 |
2493858 | SPC/GB20/022 | United Kingdom | ⤷ Try a Trial | PRODUCT NAME: DAROLUTAMIDE OPTIONALLY IN THE FORM OF A PHARMACEUTICALLY ACCEPTABLE SALT OR ESTER THEREOF; REGISTERED: UK EU/1/20/1432/001(NI) 20200330; UK PLGB 00010/0677 20200330 |
3106463 | 2020C/507 | Belgium | ⤷ Try a Trial | PRODUCT NAME: VITRAKVI - LAROTRECTINIB ET/OU SES SELS ACCEPTABLES EN PHARMACIE, EN PARTICULIER L'HYDROGENO SULFATE DE LAROTRECTINIB; AUTHORISATION NUMBER AND DATE: EU/1/19/1385 20190923 |
3106463 | LUC00150 | Luxembourg | ⤷ Try a Trial | PRODUCT NAME: LAROTRECTINIB ET/OU SES SELS PHARMACEUTIQUEMENT ACCEPTABLES, EN PARTICULIER LE SULFATE DE LAROTRECTINIB, Y COMPRIS L'HYDROGENOSULFATE DE LAROTRECTINIB; AUTHORISATION NUMBER AND DATE: EU/1/19/1385 20190923 |
1986495 | 19C1035 | France | ⤷ Try a Trial | PRODUCT NAME: COMPOSITION COMPRENANT SEDAXANE OU UN TAUTOMERE DE CE COMPOSE, FLUDIOXONIL ET METALAXYL-M; NAT. REGISTRATION NO/DATE: 2180766 20181218; FIRST REGISTRATION: NL - 15544N 20171229 |
>Patent Number | >Supplementary Protection Certificate | >SPC Country | >SPC Expiration | >SPC Description |
Similar Applicant Names
Here is a list of applicants with similar names.